Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Pharma Strategy Will Remove Barriers And Bolster Competition

Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars

Executive Summary

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

You may also be interested in...



Medicines For Europe And Czech Pharma Body Demand Access Reforms

Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.

Teva Urges Europe To Address ‘Essential Medicines Exodus’

Teva has called for action from European leaders to address the threat of an essential medicines industry “exodus” from the region, suggesting that the continent is facing a losing battle against China and India that has led to the migration of vital manufacturing assets.

EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe

The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel